1. Amikacin—Furosemide 2. Aminophylline—Ciprofloxacin 3. Aminophylline—Mexiletine 4. Amiodarone—Ciprofloxacin 5. Amiodarone—Digoxin 6. Amiodarone—Erythromycin 7. Amiodarone—Flecainide 8. Amiodarone—Itraconazole 9. Amiodarone—Procainamide 10. Amiodarone—Rifampin 11. Amiodarone—Sotalol 12. Amiodarone—Verapamil 13. Amiodarone—Diltiazem 14. Amlodipine—Rifampin 15. Atenolol—Verapamil 16. Atenolol—Diltiazem 17. Benazepril—Spironolactone 18. Benazepril—Trimethoprim 19. Carvedilol—Verapamil 20. Carvedilol—Diltiazem 21. Ciprofloxacin—Prednisolone 22. Ciprofloxacin—Procainamide 23. Ciprofloxacin—Sotalol 24. Ciprofloxacin—Theophylline 25. Cyclosporine—Itraconazole 26. Cyclosporine—Rifabutin 27. Cyclosporine—Rifampin 28. Digoxin—Dronedarone 29. Digoxin—Itraconazole 30. Enalapril—Spironolactone 31. Enalapril—Trimethoprim 32. Erythromycin—Ketoconazole 33. Erythromycin—Procainamide 34. Erythromycin—Sotalol 35. Erythromycin—Verapamil 36. Erythromycin—Diltiazem 37. Esmolol—Verapamil 38. Esmolol—Diltiazem 39. Flecainide—Procainamide 40. Flecainide—Sotalol 41. Fluticasone—Itraconazole 42. Fluticasone—Ketoconazole 43. Furosemide—Gentamicin 44. Furosemide—Kanamycin 45. Furosemide—Streptomycin 46. Furosemide—Tobramycin 47. Itraconazole—Nifedipine 48. Itraconazole—Rifabutin 49. Itraconazole—Rifampin 50. Itraconazole—Sildenafil 51. Ketoconazole—Procainamide 52. Ketoconazole—Rifabutin 53. Ketoconazole—Rifampin 54. Ketoconazole—Rifapentine 55. Ketoconazole—Sotalol 56. Metoprolol—Verapamil 57. Metoprolol—Diltiazem 58. Mexiletine—Theophylline 59. Nifedipine—Phenobarbital 60. Nifedipine—Phenytoin 61. Nifedipine—Rifabutin 62. Nifedipine—Rifampin 63. Nifedipine—Rifapentine 64. Procainamide—Sotalol 65. Ramipril—Spironolactone 66. Ramipril—Trimethoprim 67. Salmeterol—Itraconazole 68. Salmeterol— Ketoconazole 69. Sotalol—Verapamil 70. Sotalol—Diltiazem 71. Spironolactone—Trimethoprim | Additive or synergistic toxicity Decreased clearance of Theophylline by Ciprofloxacin Decreased hepatic metabolism Additive effects on QT interval P-glycoprotein inhibition by Amiodarone Additive effects on QT prolongation, CYP3A4 inhibition by Erythromycin Antiarrhythmic inhibition by Amiodarone, CYP2D6 inhibition by Amiodarone CYP3A4 inhibition by Itraconazole Antiarrhythmic inhibition by Amiodarone CYP induction by Rifampin Additive effects on refractory potential CYP3A4 inhibition by Verapamil CYP3A4 inhibition by Diltiazem CYP induction by Rifampin Additive cardiovascular effects, decreased metabolism of some beta-blockers by Verapamil Additive cardiovascular effects, decreased metabolism of some beta-blockers by Diltiazem Increased potassium retention secondary to lowered aldosterone levels Additive effects of hyperkalemia Additive cardiovascular effects, decreased metabolism of some beta-blockers by Verapamil Additive cardiovascular effects, decreased metabolism of some beta-blockers by Diltiazem An additive effect of risk for tendon rupture Additive effects on the QT interval Additive effects on the QT interval Decreased clearance of Theophylline, CYP1A2 inhibition by Ciprofloxacin CYP3A4 inhibition by Itraconazole Cyclosporine metabolism induction by Rifabutin Increased Cyclosporine clearance and decreased systemic bioavailability by Rifampin P-glycoprotein inhibition by Dronedarone Digoxin metabolism and clearance inhibition by Itraconazole Increased potassium retention secondary to lowered aldosterone levels Additive effects of hyperkalemia CYP3A4 inhibition by Erythromycin and Ketoconazole CYP3A4 inhibition by Erythromycin Additive effects on QT prolongation CYP3A4 inhibition by Erythromycin CYP3A-mediated inhibition by Diltiazem Additive cardiovascular effects, decreased metabolism of some beta-blockers by Verapamil Additive cardiovascular effects, decreased metabolism of some beta-blockers by Diltiazem Additive effects on QT prolongation Additive effects on refractory potential CYP3A-mediated inhibition by Itraconazole CYP3A-mediated inhibition by Ketoconazole Additive or synergistic toxicity Additive or synergistic toxicity Additive or synergistic toxicity Additive or synergistic toxicity CYP3A4 inhibition by Itraconazole CYP3A4 induction by Rifabutin, CYP3A4 inhibition by Itraconazole CYP3A-mediated induction by Rifampin CYP3A4 inhibition by Itraconazole Additive QT-interval prolongation CYP3A-mediated inhibition by Ketoconazole, CYP3A-mediated induction by Rifabutin CYP3A-mediated induction by Rifampin CYP3A4 induction by Rifapentine Additive effects on the QT interval Additive cardiovascular effects, decreased metabolism of some beta-blockers by Verapamil Additive cardiovascular effects, decreased metabolism of some beta-blockers by Diltiazem Decreased hepatic metabolism, CYP1A2 inhibition by Mexiletine CYP3A4 induction by Phenobarbital CYP3A4 induction by Phenytoin CYP3A4 induction by Rifabutin CYP3A4 induction by Rifampin CYP3A4 induction by Rifapentine Additive effects on refractory potential Increased potassium retention secondary to lowered aldosterone levels Additive effects of hyperkalemia CYP3A-mediated inhibition by Itraconazole CYP3A-mediated inhibition by Ketoconazole Additive cardiovascular effects, decreased metabolism of some beta-blockers by Verapamil Additive cardiovascular effects, decreased metabolism of some beta-blockers by Diltiazem Additive effects of hyperkalemia |